Gynecologic Oncology | Interview with Kathleen Moore, MD

Beyond the Guidelines: Perspectives on the Role of PARP Inhibition in the Management of Ovarian Cancer — Interview with Dr Moore on the following topics: Genomic testing for patients with newly diagnosed ovarian cancer (OC) (00:00) Management of OC with germline BRCA mutation after surgical debulking; role of bevacizumab and PARP inhibitors (3:40) Therapeutic approach for patients with homologous recombination-proficient OC (8:20) CME information and select publications